SQLite Web: event_store.db

Update row 21803 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:a1643dfb4d5ecb45","evidence_event_ids":["evt_79dbdc7a374f"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150469.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150469.txt","company":"Tempest Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150469.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_ecb6c9cae8c6c3be","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150469.txt","content_type":"text/plain","enriched_at":"2026-04-11T06:08:05.982174+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"424B3","final_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150469.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150469.txt","source_event_id":"evt_79dbdc7a374f","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"424B3","fp":"6bf41e3e6480767e","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-10","2026-04-11","2026-04-03","2026-04-02","2025-11-19","February 2026"],"entities":[{"asset_class":"equity","name":"Tempest Therapeutics, Inc.","relevance":"high","symbol":"TPST","type":"issuer"},{"asset_class":"equity","name":"Selling stockholders (named herein)","relevance":"medium","symbol":"","type":"counterparty_group"}],"event_type":"listing","information_gaps":["What specifically changed vs prior known state is not provided in the signal (no prior filing/state content included).","The prospectus excerpt does not include the full \u201cProspectus Summary\u201d or details of the asset acquisition beyond the stated existence of the asset purchase agreement.","No information is provided here about the identity of the selling stockholders, the exact number of shares each will sell, or any pricing/volume limits beyond general \u201cfrom time to time\u201d language.","The excerpt truncates the \u201cCompany Overview\u201d section mid-sentence, so pipeline/transaction details are incomplete."],"key_facts":["Form 424B3 filed pursuant to Rule 424(b)(3) for Registration No. 333-294740.","Prospectus covers resale/offer of up to 8,268,495 shares of Tempest Therapeutics, Inc. common stock (par value $0.001 per share).","Shares are to be offered by selling stockholders named in the prospectus (and additional selling stockholders in supplements).","Selling stockholders acquired the shares pursuant to an asset purchase agreement dated November 19, 2025.","The company will not receive any proceeds from sales of the shares by selling stockholders.","Selling stockholders bear underwriting fees/commissions/discounts (if any) and transfer taxes attributable to the sales; the company bears other registration costs/expenses.","Company common stock is listed on The Nasdaq Capital Market under trading symbol TPST.","On April 2, 2026, the closing price of common stock was $1.59 per share.","Prospectus date is April 3, 2026; it is part of an S-3 shelf registration statement filed with the SEC.","The prospectus includes risk-factor disclosure and standard SEC approval disclaimer."],"numeric_claims":[{"label":"shares_registered","value":"8,268,495"},{"label":"common_stock_par_value_usd","value":"0.001"},{"label":"closing_price_apr_2_2026_usd","value":"1.59"},{"label":"asset_purchase_agreement_date","value":"2025-11-19"},{"label":"prospectus_date","value":"2026-04-03"}],"primary_claim":"The Form 424B3 prospectus registers the offer and resale from time to time of up to an aggregate 8,268,495 shares of Tempest Therapeutics, Inc. common stock by selling stockholders, with no proceeds to the company.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Tempest Therapeutics, Inc. filed a Form 424B3 prospectus (dated April 3, 2026) covering resale of up to 8,268,495 shares of its common stock by selling stockholders. The filing states the company will not receive proceeds from those sales and that the shares were acquired under an asset purchase agreement dated November 19, 2025.","topics":["SEC filing","Form 424B3","prospectus","common stock resale","registration rights","asset purchase agreement","Nasdaq TPST","risk factors"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 424B3 \u00b7 Tempest Therapeutics, Inc. \u00b7 Filed 20260410","ticker":"TPST","tickers":["TPST"],"title":"TPST filed 424B3","url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150469.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel